吡格列酮对2型糖尿病患者血清脂联素与胰岛素抵抗的影响

目的探讨吡格列酮对2型糖尿病患者血清脂联素水平及胰岛素抵抗的影响。方法2型糖尿病患者45例，两组年龄、性别匹配，按随机双盲法分为吡格列酮组（22例）和安慰剂组（23例），干预治疗12周后比较其血清脂联素、游离脂肪酸（FFA）水平，同时测血糖、血压、血脂、身高、体重、腰围、臀围，计算体重指数（BMI）、腰臀比值（WHR）、空腹胰岛素（Fins）和胰岛13细胞功能（HOMA-IR）。结果治疗前两组的脂联素、游离脂肪酸水平无明显差别，经吡格列酮治疗后，患者血糖、胰岛素抵抗明显改善（P〈0．05），血清脂联素水平显著升高（P〈0．05），血清FFA水平下降（P〈0．05），血清脂联素升高与FFA下降无显著相关性（P〉0．05）。结论吡格列酮除改善血糖及胰岛素抵抗外，还可使血清脂联素水平升高，FFA水平降低，提示吡格列酮可能通过降低FFA、升高脂联素水平改善2型糖尿病患者胰岛素抵抗。

Effects of pioglitazone on serum adiponectin levels and insulin resistance in patients with type 2 diabetes mellitus

Aim To discuss the effects of pioglitazone on serum adiponectin levels and insulin resistance in patients with type 2 diabetes mellitus.Methods Forty-five subjects with type 2 diabetes mellitus which were matched with age and gender were assigned to either pioglitazone group or placebo group according to randomized,double-blind method(22 and 23 subjects respectively).Comparison of serum adiponectin,free fatty acid levels at baseline and after 12 weeks,together the levels of blood glucose,blood pressure,bloo...